CancerLinQ LLC, a wholly owned nonprofit subsidiary of ASCO, has announced an exciting new benefit for practices participating in CancerLinQ™. Current and future early adopters of CancerLinQ who sign up before
ASCO’s 2017 Annual Meeting will receive a complimentary subscription to ASCO University Essentials, which includes access to the ASCO University eLearning catalog, ASCO’s personalized learning dashboard, and ASCO’s MOC app.
“Early adopters of CancerLinQ™ represent practices who are committed to enhancing and improving patient outcomes,” said CancerLinQ LLC CEO Kevin Fitzpatrick. “ASCO University, the eLearning Center of ASCO, will give early adopters an additional method to strengthen their practice, enhance the value of ASCO membership, and expand their knowledge.”
CancerLinQ™ is a powerful platform containing growing amounts of real-world cancer information. This national initiative will allow cancer providers to improve the quality and value of care by analyzing millions of cancer patient medical records, uncovering patterns and trends, and measuring their care against that of their peers and recommended guidelines. The platform uses SAP Connected Health built on the SAP HANA® platform, a flexible, multipurpose data management and application platform created by SAP.
ASCO University Essentials offers unlimited access to all of ASCO University’s eLearning courses. With over 100 online courses covering all areas of oncology available, practices gain valuable current clinical care learning modules for physicians, nurses, and advanced practitioners. With new content added monthly, courses include a variety of case-based scenarios on specific disease sites, including the Immuno-Oncology Program, the Tumor Genomics Program, the Cancer Genetics Program, the ASCO Tumor Board Series, and the Molecular Oncology Tumor Boards. CME, ABIM MOC, nursing, and pharmacy credit is available. Check each course for details.
CancerLinQ is a project of CancerLinQ LLC. For more information, please visit CancerLinQ.org. ■
© 2016. American Society of Clinical Oncology. All rights reserved.
